Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Thrombosis research. Supplement

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0049-3848(90)90373-KPMID 2315899
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1).

  1988cited by this paper
• Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

  1988cited by this paper
• AN IMMUNOFUNCTIONAL ASSAY FOR ACTIVE PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)

  1988cited by this paper
• Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3.

  1987cited by this paper
• Immunological Relationship Between Plasminogen Activator Inhibitors from Different Sources

  1987cited by this paper
• Deficient t-PA Release and Elevated PA Inhibitor Levels in Patients with Spontaneous or Recurrent Deep Venous Thrombosis

  1987cited by this paper
• Measurement of free, one-chain tissue-type plasminogen activator in human plasma with an enzyme-linked immunosorbent assay based on an active site-specific murine monoclonal antibody.

  1987cited by this paper
• Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation.

  1987cited by this paper
• Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.

  1986cited by this paper
• Method for the determination of fast acting plasminogen activator inhibitor capacity (PAI-cap) in plasma, platelets and endothelial cells.

  1986cited by this paper
• Plasminogen activator inhibitor in the blood of patients with coronary artery disease.

  1985cited by this paper
• Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.

  1985cited by this paper
• Problems on t-PA Specific Inhibitor Determination in Human Plasma

  1985cited by this paper
• Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator.

  1985cited by this paper
• Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA

  1985cited by this paper
• Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

  1984cited by this paper
• Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma.

  1984cited by this paper
• Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Evidence for a rapid plasminogen activator inhibitor.

  1984cited by this paper
• Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions.

  1984cited by this paper
• Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma

  1984cited by this paper
• Evidence for a rapid inhibitor to tissue plasminogen activator in plasma.

  1983cited by this paper
• [1] Preparation of monoclonal antibodies: Strategies and procedures

  1981cited by this paper
• Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

  1978cited by this paper
• PEROXIDASE-LABELED ANTIBODY A NEW METHOD OF CONJUGATION

  1974cited by this paper
• Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane)

  1969cited by this paper

• Investigating Serum Dairy Fatty Acid Biomarkers and their Association with Type 2 Diabetes and its Underlying Disorders

  2014cites this paper
• Clinical Application of Fibrinolytic Assays

  2014cites this paper
• Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?

  2014cites this paper
• Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

  2012cites this paper
• The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)

  2012cites this paper
• Pentoxifylline Lowers Plasminogen Activator Inhibitor 1 Levels in Obese Individuals: A Pilot Study

  2012cites this paper
• interaction sites and physiologic relevance activators (tissue-type and urokinase-type) and fibrin: localization of The interaction of plasminogen activator inhibitor 1 with plasminogen

  2011cites this paper
• Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1

  2011cites this paper
• Significant inverse associations of serum n-6 fatty acids with plasma plasminogen activator inhibitor-1

  2011cites this paper
• n-3 and n-6 Polyunsaturated Fatty Acids and Vitamin D related to Subclinical Atherosclerois in the ERA-Jump Study

  2011cites this paper
• Prognostic value of plasma fibrinolysis activation markers in cardiovascular disease.

  2010cites this paper
• Whole and refined grain intakes are related to inflammatory protein concentrations in human plasma.

  2010cites this paper
• Risk of type 2 diabetes among individuals with high and low glomerular filtration rates

  2009cites this paper
• Intakes of Whole and Refined Grains and Dietary Fibre In Relation to Plasma Inflammatory Protein Concentrations

  2009cites this paper
• Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort

  2009cites this paper
• Inhibition of kinin metabolism and the role of the vascular B₁ kinin receptor in patients with congestive heart failure

  2008cites this paper
• Acute Effects of Glucocorticoids on Endothelial Fibrinolytic and Vasodilator Function in Humans

  2007cites this paper
• Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis.

  2007cites this paper
• No functional role of plasminogen activator inhibitor‐1 in murine adipogenesis or adipocyte differentiation

  2007cites this paper
• Inflammation, local vascular glucocorticoid regulation and endothelial function

  2006cites this paper
• Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes

  2006cites this paper
• Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.

  2006cites this paper
• African American Women, Metabolic Syndrome, and National Cholesterol Education Program Criteria: A Pilot Study

  2005cites this paper
• Central Obesity, the Metabolic Syndrome, and Plasminogen Activator Inhibitor‐1 in Young Adults

  2005influential citation
• A unique collaboration on a national goal.

  2005cites this paper
• African American women, metabolic syndrome, and national cholesterol education program criteria: a pilot study.

  2005cites this paper
• Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity.

  2004cites this paper
• Protease Nexin-1 Inhibits Plasminogen Activation-induced Apoptosis of Adherent Cells*

  2004cites this paper
• Specificityof Antigen Assays of Plasminogen Activator Inhibitor in Plasma : Innotest PAli Immunoassay Evaluated

  2004cites this paper
• The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

  2004cites this paper
• Induction of Apoptosis in Vascular Cells by Plasminogen Activator Inhibitor-1 and High Molecular Weight Kininogen Correlates with Their Anti-Adhesive Properties

  2003cites this paper
• Inflammation in the Prediabetic State Is Related to Increased Insulin Resistance Rather Than Decreased Insulin Secretion

  2003cites this paper
• Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors?

  2003cites this paper
• mutant resistant to plasminogen activator inhibitor-1 recombinant human tissue-type plasminogen activator deletion Biochemical and biologic properties of rt-PA del ( K 296-G 302 )

  2003cites this paper
• Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system

  2003cites this paper
• Enzyme immunoassay for measurement of murine plasminogen activator inhibitor-1, employing a specific antibody produced by the DNA vaccine method.

  2003cites this paper
• Prospective study of fibrinolytic markers and venous thromboembolism.

  2003cites this paper
• Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study

  2003cites this paper
• No Association of Plasma Prothrombin Concentration or the G20210A Mutation with Incident Cardiovascular Disease

  2002cites this paper
• Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.

  2002cites this paper
• Glycosylation dependent conformational transitions in plasminogen activator inhibitor-1: evidence for the presence of two active conformations

  2000cites this paper
• Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects.

  2000cites this paper
• Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.

  1999cites this paper
• Hormone replacement therapy, inflammation, and hemostasis in elderly women.

  1999cites this paper
• Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

  1999cites this paper
• Modulation of Pro- and Antifibrinolytic Properties of Human Peritoneal Mesothelial Cells by Transforming Growth Factor β1 (TGF- β1), Tumor Necrosis Factor α (TNF-α) and Interleukin β1 (IL-1β)

  1998cites this paper
• Correlates of Antithrombin, Protein C, Protein S, and TFPI in a Healthy Elderly Cohort

  1998cites this paper
• lin . Proinsulin is increased relative to insulin in subjects with type 2 diabetes in all studies

  1998cites this paper
• Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study.

  1998cites this paper
• Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators.

  1998cites this paper
• Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor‐1 neutralizing effects

  1997cites this paper
• Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.

  1995cites this paper
• Specificity of AntigenAssaysof Plasminogen ActivatorInhibitorin Plasma:Innotest PAl-i Immunoassay Evaluated

  1994cites this paper
• Multicenter Evaluation of Commercially Available Methods for the Immunological Determination of Plasminogen Activator Inhibitor-1 (PAI-1)

  1993cites this paper
• Fibrinolytic parameters and hemostatic monitoring: identifying and predicting patients at risk for major hemorrhagic events.

  1992cites this paper
• A Specific Immunologic Assay for Functional Plasminogen Activator Inhibitor 1 in Plasma – Standardized Measurements of the Inhibitor and Related Parameters in Patients with Venous Thromboembolic Disease

  1992influential citation
• Increased release of tissue plasminogen activator and its inhibitor in human parotid saliva upon stimulation.

  1992cites this paper
• Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.

  1992cites this paper
• Inhibition of Plasminogen Activator Inhibitor‐1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Extension in Models of Experimental Thrombosis

  1992cites this paper
• The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia

  1991cites this paper
• The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.

  1991cites this paper
• The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.

  1991cites this paper
• Measurement of different forms of plasminogen activator inhibitor 1(PAI-1) using various monoclonal antibody-based enzyme-linked immunosorbent assays

  1990cites this paper